Table 1 Information about the active substances included in the study
Active ingredient | Marketing authorization | Generic substitution | Reference pricing | Total costs (EUR) | Purchasing individuals (n) | ||
|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | 2006 | 2010 | 2006 | 2010 |
Clozapine | 1990 | 1st Jan 2006 | 1st Apr 2009 | 4,457,941 | 5,356,410 | 7,773 | 9,227 |
Olanzapine | 1996 | 1st Apr 2009 | 1st Apr 2009 | 37,287,194 | 21,819,898 | 20,151 | 22,857 |
Quetiapine | 2001 | 1st Apr 2009 | 1st Apr 2009 | 23,076,154 | 20,235,274 | 29,793 | 65,351 |
Risperidone | 1994 | 1st Jan 2008 | 1st Apr 2009 | 21,411,458 | 16,780,347 | 28,997 | 37,220 |